Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620398
Title:
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Authors:
Earl, H; Hiller, L; Howard, H; Dunn, J; Young, J; Bowden, S; McDermaid, M; Waterhouse, A; Wilson, Gregory; Agrawal, R; O'Reilly, S; Bowman, A; Ritchie, D; Goodman, A; Hickish, T; McAdam, K; Cameron, D; Dodwell, D; Rea, D; Caldas, C; Provenzano, E; Abraham, J; Canney, P; Crown, J; Kennedy, M; Coleman, R; Leonard, R; Carmichael, J; Wardley, Andrew M ( 0000-0002-9639-0888 ) ; Poole, C
Abstract:
The tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel.
Affiliation:
Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Cambridge UK
Citation:
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. 2017, 18 (6):755-769 Lancet Oncol
Journal:
The Lancet Oncology
Issue Date:
Jun-2017
URI:
http://hdl.handle.net/10541/620398
DOI:
10.1016/S1470-2045(17)30319-4
PubMed ID:
28479233
Type:
Article
Language:
en
ISSN:
1474-5488
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorEarl, Hen
dc.contributor.authorHiller, Len
dc.contributor.authorHoward, Hen
dc.contributor.authorDunn, Jen
dc.contributor.authorYoung, Jen
dc.contributor.authorBowden, Sen
dc.contributor.authorMcDermaid, Men
dc.contributor.authorWaterhouse, Aen
dc.contributor.authorWilson, Gregoryen
dc.contributor.authorAgrawal, Ren
dc.contributor.authorO'Reilly, Sen
dc.contributor.authorBowman, Aen
dc.contributor.authorRitchie, Den
dc.contributor.authorGoodman, Aen
dc.contributor.authorHickish, Ten
dc.contributor.authorMcAdam, Ken
dc.contributor.authorCameron, Den
dc.contributor.authorDodwell, Den
dc.contributor.authorRea, Den
dc.contributor.authorCaldas, Cen
dc.contributor.authorProvenzano, Een
dc.contributor.authorAbraham, Jen
dc.contributor.authorCanney, Pen
dc.contributor.authorCrown, Jen
dc.contributor.authorKennedy, Men
dc.contributor.authorColeman, Ren
dc.contributor.authorLeonard, Ren
dc.contributor.authorCarmichael, Jen
dc.contributor.authorWardley, Andrew Men
dc.contributor.authorPoole, Cen
dc.date.accessioned2017-06-29T10:06:50Z-
dc.date.available2017-06-29T10:06:50Z-
dc.date.issued2017-06-
dc.identifier.citationAddition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. 2017, 18 (6):755-769 Lancet Oncolen
dc.identifier.issn1474-5488-
dc.identifier.pmid28479233-
dc.identifier.doi10.1016/S1470-2045(17)30319-4-
dc.identifier.urihttp://hdl.handle.net/10541/620398-
dc.description.abstractThe tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel.en
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleAddition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Addenbrooke's Hospital, University of Cambridge, Cambridge UKen
dc.identifier.journalThe Lancet Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.